NCT00581789View on ClinicalTrials.gov

Erlotinib and Sunitinib in NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

August 31, 2011

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

erlotinib, sunitinib

erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)

Trial Locations (1)

53792

University of Wisconsin Carbone Comprehensive Cancer Center, Madison

Sponsors

Collaborators (2)

Pfizer
Genentech, Inc.
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER